Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.
Also called NCT03620890
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 108 participants
- Registry
-
NCT03620890
-
- Main results
- Detemir vs neutral protamine Hagedorn insulin for diabetes mellitus in pregnancy: a comparative effectiveness, randomized controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03620890. Randomized; no masking; primary purpose treatment. Start 2018-09-04 (actual); primary completion 2020-07-29 (actual). Results posted on 2021-08-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
- Acronym
- Determin
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Neutral Protamine Hagedorn (NPH)
- Intervention (Drug)
- Detemir insulin
- Lead sponsor
- The University of Texas Health Science Center, Houston
Record details
- Record id
cardio:ct-nct03620890- Content hash
afa6b86c3dbf6b6b3bcea39013650f9e6a7ba0e841d4f70c3d81f232037aca1a